Last updated: February 19, 2026
What is NDC 59651-0030?
NDC 59651-0030 is a drug marketed under the brand name Zolgensma, a gene therapy developed by Novartis. It is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients, including those with overlapping symptoms regardless of age at treatment initiation. Zolgensma is delivered as a single intravenous infusion.
Market Size and Demographics
Patient Population
- Estimated SMA prevalence: Approximately 1 in 10,000 live births.
- Estimated treated population:
- Infants with SMA Type 1: around 1,200 annually in the U.S.
- Broader SMA spectrum (including Types 2 and 3): up to 2,500 worldwide.
Key Markets
| Region |
Estimated Annual SMA Patients |
Market Penetration |
Estimated Treatment Rate |
| United States |
1,200 |
90% in specialized centers |
1,080 |
| European Union |
1,200 |
80% in specialized centers |
960 |
| Rest of World |
100 |
Limited access |
50 |
Competitive Landscape
- Competition from other SMA therapies, e.g., Biogen's Spinraza (nusinersen) and Edison gene therapy (pending approval).
- SMA treatment increasingly shifted toward gene therapy via affordability and shorter treatment regimens.
Price Structure and Reimbursement
List Price
- USA: Approximate list price of $2.1 million per infusion.
- Europe: Similar pricing, typically between €1.9-2.3 million.
- Other Markets: Prices vary based on local regulations and negotiations.
Reimbursement Policies
- U.S.: Varied by insurer; value-based agreements are increasingly common.
- Europe: Cost-effectiveness evaluations by agencies like NICE influence access and pricing.
- Pricing Models: One-time payment with outcomes-based agreements; some use installment payments.
Market Trends and Drivers
Growth Drivers
- Increased early diagnosis through newborn screening programs.
- Expanded approval for broader age groups and SMA types.
- Patent rights and exclusivity extending to 2030–2035.
- Growing awareness and access in emerging markets.
Challenges
- High upfront cost leading to payer resistance.
- Limited manufacturing capacity constraining supply.
- Competition from alternative gene and RNA-based therapies.
Price Projections
| Year |
Estimated Average Price (USD) |
Drivers |
Risks |
| 2023 |
$2.1 million |
Stable demand; ongoing negotiations with payers |
Regulatory delays; price compressions from competitors |
| 2024 |
$2.0 million |
Early adoption plateau; price negotiations intensify |
Payer pushback; emergence of biosimilars or generics |
| 2025 |
$1.9 million |
Market stabilization; discounts for wider access |
Patent expiration; entry of alternative therapies |
| 2026+ |
$1.8 million to $1.7 million |
Increased manufacturing capacity; biosimilar activity |
Patent expiry; regulatory changes evolve |
Key Market and Pricing Considerations
- Pricing flexibility: Manufacturers often provide installment and value-based agreements.
- Access expansion: Lowering effective prices via negotiations, discounts, and patient assistance programs.
- Regulatory environment: Price controls in European markets influence long-term pricing.
Summary of Market Risks and Opportunities
| Risks |
Opportunities |
| Payer resistance due to high cost |
Growing patient pool from newborn screening |
| Patent expiration approaching in 2030–2035 |
Expansion to new indications and age groups |
| Market entry of biosimilars or new gene therapies |
Strategic partnerships and regional expansion |
Key Takeaways
- NDC 59651-0030 (Zolgensma) commands a premium pricing point, approximately $2.1 million per dose in the U.S.
- The market remains constrained by payer resistance and manufacturing capacity but benefits from expanding diagnoses via newborn screening.
- Price projections suggest gradual declines to around $1.7–$1.9 million by 2026, driven by market stabilization, negotiations, and biosimilar activity.
- Longer-term growth relies on expanding indications, age groups, and geographic access.
FAQs
Q1: What factors influence the pricing of Zolgensma globally?
A1: Regulatory approval status, local pricing regulations, market size, negotiation power of payers, and competition influence the pricing of Zolgensma.
Q2: How does reimbursement vary between markets?
A2: The U.S. employs largely private insurance and Medicaid, with value-based agreements emerging. Europe relies on health technology assessments, which can restrict reimbursement or demand discounts.
Q3: What impact could biosimilars have on Zolgensma’s price?
A3: Biosimilars could introduce price competition, possibly lowering prices by 20-40% once patents expire around 2030–2035.
Q4: Are there any emerging therapies that could disrupt the market?
A4: Yes, gene editing approaches, alternative gene therapy vectors, and RNA-based treatments are potential disruptors pending regulatory approval and clinical success.
Q5: What is the outlook for treatment access in emerging markets?
A5: Access is limited due to high costs and regulatory challenges, but local pricing negotiations and international aid could improve availability over time.
Sources
[1] Novartis. (2022). Zolgensma prescribing information.
[2] IQVIA. (2023). Global medicine pricing and reimbursement trends.
[3] European Medicines Agency. (2023). Assessment reports on SMA therapies.
[4] US Food and Drug Administration. (2022). Approval documents for Zolgensma.
[5] MarketResearch.com. (2023). SMA market and gene therapy forecasts.
